IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.69-$14.94 to $14.96-$15.16 vs $14.82 Est; Raises FY2026 Sales Guidance from $4.700B-$4.745B to $4.741B-$4.767B vs $4.723B Est

IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.69-$14.94 to $14.96-$15.16 vs $14.82 analyst estimate. Raises FY2026 sales outlook from $4.700 billion-$4.745 billion to $4.741 billion-$4.767 billion vs $4.723 billion estimate.